linjc16/ctgov huggingface dataset:
interACTION: A Portable Joint Function Monitoring and Training System to Supplement Home Exercise Programs Following Anterior Cruciate Ligament Reconstruction

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to ascertain if home-based therapy with monitoring via telemedicine can overcome many barriers to compliance and improve rehabilitation following ACL reconstruction. Patients undergoing ACL Reconstruction will be followed for 6 weeks during their outpatient physical therapy treatment. Subjects will undergo weekly physical therapy or weekly physical therapy paired with InterACTION.

Official Title
-----------------
interACTION: A Portable Joint Function Monitoring and Training System to Supplement Home Exercise Programs Following Anterior Cruciate Ligament Reconstruction

Conditions
-----------------
Anterior Cruciate Ligament Reconstruction

Intervention / Treatment
-----------------
* Device: interACTION
* Other: Standard of Care Physical Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between 15 to 30 years of age; Have undergone ACL Reconstruction; Being referred for post-operative outpatient physical therapy; Agree to and able to perform pre-designed exercises that they would normally perform in a physical therapy program after ACL Reconstruction. Exclusion Criteria: Patients undergoing concomitant meniscal repair or other surgical procedure requiring modification of post-operative physical therapy program; Patients with BMI >40 at the time of surgery; Individuals who are not free of any other co-disability or comorbidity that would specifically impede disallow or otherwise hinder performance of physical therapy exercises;

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Physical Therapy with InterACTION<br>After ACL Reconstruction, subjects will undergo physical therapy 1 time per week supplemented by home exercise program with InterACTION device. | Device: interACTION<br> <br> |
| Other: Physical Therapy<br>After ACL Reconstruction, subjects will undergo physical therapy 1 time per week | Other: Standard of Care Physical Therapy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Value evaluated by the ratio of patient outcomes to costs of rehabilitation | Value will be evaluated by the ratio of patient outcomes to costs of rehabilitation | 6 weeks |
A Randomized Blinded Trial of Abscess Management With Packing vs No Packing

Study Overview
=================
Brief Summary
-----------------
Adult patients presenting to the emergency department with superficial cutaneous abscesses will be randomized after incision and drainage to standard care with wound packing or no packing to determine if there is a difference in the proportion of complications between the two groups.

Official Title
-----------------
A Randomized Blinded Trial of Abscess Management With Packing vs No Packing

Conditions
-----------------
Uncomplicated Cutaneous Abscess

Intervention / Treatment
-----------------
* Procedure: Packing vs No Packing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥ 18 years Abscess ≤ 5cm in diameter Truncal or extremity location Exclusion Criteria: Post-operative abscess (abscess in location of operative incision, operation within the last 4 months) HIV/immunocompromised/transplant recipient/chronic oral steroid use Fever at triage (temp ≥38 degrees Celsius) Abscess secondary to Crohn's Multiple abscesses requiring drainage Prior participation in the study for the same abscess Incision and drainage performed with no packing required, or where abscess cavity is <1 cm max diameter Bartholins/perigenital, perianal, or facial abscesses Complicated abscesses (fistula, suspicion of muscular extension, consultation/direct referral to general surgery) Inability to give consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: No Packing<br>No Packing | Procedure: Packing vs No Packing<br> <br> |
| Experimental: Packing<br>Packing | Procedure: Packing vs No Packing<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of complications (defined as a composite of the following: need for repeat incision and drainage by physician, need for admission to hospital, or need for escalation to intravenous antibiotics) |  | 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of wounds closed at 1 week (wound size <0.5 cm length and depth and no drainage) |  | 7 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
abscess, packing, emergency medicine, wound care, incision and drainage
Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS (ECTOP-1011)

Study Overview
=================
Brief Summary
-----------------
This study is one of the Eastern Cooperative Thoracic Oncology Projects (ECTOP-1011). It aims to evaluate the correlations between radiologic features and pathologic subtypes of ground glass opacity featured lung adenocarcinoma via whole-mount section.

Detailed Description
-----------------
The pathological lepidic growth pattern was believed to relate to the ground-glass component, whereas invasive adenocarcinoma patterns relate to the solid component. However, the solid components might be fibrosis rather tumor; and previous studies demonstrated the ground-glass components might be invasive lesions. Therefore, it is of considerable significance to establish the correlations between radiologic features and pathologic subtypes of ground glass opacity featured lung adenocarcinoma.

Official Title
-----------------
Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of Ground Glass Opacity Featured Lung Adenocarcinoma Via Whole-Mount Section

Conditions
-----------------
Adenocarcinoma of Lung

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ground glass opacity featured lung nodule diagnosed by thin-section computed tomography(TSCT) Pre-operation clinical IA stage Pulmonary lobectomy or segmentectomy Provision of informed consent Exclusion Criteria: Postoperative diagnosis of non-adenocarcinoma or mucinous adenocarcinoma The surgical specimens fail to satisfy requirement of inflation and formalin fixation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients<br>Patients with ground glass opacity featured lung adenocarcinoma who are candidates for surgery. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of correlations between radiologic features and pathologic subtypes | Evaluation of correlations between radiologic features and pathologic subtypes of ground glass opacity featured lung adenocarcinoma | about 14 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Specificity, Sensitivity, and Repeatability | The specificity, sensitivity, and repeatability of invasiveness diagnosis based on the Whole-Mount Section | about 14 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ground glass opacity
Clinical Presentations Before AMI Onset and Coronary Atherosclerosis

Study Overview
=================
Brief Summary
-----------------
This study aimed to evaluate the incidence of preinfarction angina in AMI patients and test the hypothesis that different clinical presentations before AMI onset can affect coronary plaque morphologies in AMI patients .

Detailed Description
-----------------
Patients with AMI who underwent primary percutaneous coronary intervention（PCI） and optical coherence tomography (OCT) examination is expected to be included in this study.Data about history were prospectively collected by a standard questionaire ,especially regarding the detail information about preinfarction angina.The basic clinical characteristics,angiographic and OCT findings are compared between patients with and without preinfarction angina.

Official Title
-----------------
Pre-infarction Angina and Culprit Plaque Characteristics in Patients With STEMI

Conditions
-----------------
Acute Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria： Men or non-pregnant women >18 years of age and < 85 years of age; Patients undergo cardiac catheterization for AMI; Patients able to provide written informed consent. Exclusion Criteria: Patients cant afford medical history; Cardiac shock； Severe left ventricular dysfunction; Left main disease; Hepatic or kidney dysfunction; OCT was performed after predilation; Poor OCT image or massive thrombus.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in culprit lesion morphologies assessed by OCT according to the presence or absence of PIA | Plaque rupture was defined by the presence of a cavity formation in the plaque with a discontinuity of the fibrous cap. TCFA was defined as a lipid-rich plaque with a thin fibrous cap thickness of ≤ 65 um.Thrombus was identified by OCT as an irregular mass ≧0.25 mm in diameter protruding into the vessel lumen or attached to the surface of the vessel wall.Culprit lesion features in patients with PIA show a lower incidence of plaque rupture and TCFA compared to those without PIA. | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-hospital outcomes after AMI. | Infarct size was measured as the peak cardiac troponin I (cTnI) level.PIA is associated with lower infarct size and lower in-hospital mortality. | baseline |
A Retrospective Study on Drug Induced Liver Injury in China

Study Overview
=================
Brief Summary
-----------------
This is a multi-center, open-enrollment, retrospective, non-interventional epidemiologic study without any clinical treatment. Its primary objective is to understand 1) incidence of drug-induced liver injury, including incidences among all the hospitalized patient, among patients in department of hepatic diseases, digestive diseases, oncology, hematology etc., individually; 2) epidemiologic characteristics of drug-induced liver injury, including suspected medications, clinical types, histological characteristics, severity and outcomes.

Detailed Description
-----------------
This is a multi-center, open-enrollment, retrospective, non-interventional epidemiologic study without any clinical treatment. Its primary objective is to understand 1) incidence of drug-induced liver injury, including incidences among all the hospitalized patient, among patients in department of hepatic diseases, digestive diseases, oncology, hematology etc., individually; 2) epidemiologic characteristics of drug-induced liver injury, including suspected medications, clinical types, histological characteristics, severity and outcomes. It investigates medical records of patients who were hospitalized during 2012 to 2014. Those patients should be diagnosed as drug-induced liver injury, drug-induced liver disease, drug-induced hepatitis, drug-induced hepatocirrhosis, drug-induced hepatic failure, or any other similar diagnosis of drug-induced liver injury nature.

Official Title
-----------------
A Retrospective Epidemiologic Study on Incidence and Treatment Status of Hospitalized Drug Induced Liver Injury Patients in Mainland China

Conditions
-----------------
Drug-Induced Liver Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any hospitalized patients who were diagnosed as drug-induced liver injury, drug-induced liver disease, drug-induced hepatitis, drug-induced hepatocirrhosis, drug-induced hepatic failure, or any other similar diagnosis of drug-induced liver injury nature. The drug-induced liver injury and similar diagnosis were not excluded the possibility of drug-induced nature. Exclusion Criteria: Confirmed non-drug induced liver injury. Insufficient clinical data supporting the diagnosis of drug-induced liver injury. Liver injury resulted from poisons and chemicals.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| diagnosis of drug-induced liver injury |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
DILI, Drug-Induced Liver Injury
Effect of Saccharomyces Cerevisiae on the Symptoms of Irritable Bowel Syndrome

Study Overview
=================
Brief Summary
-----------------
The main purpose of this study is the effect of the probiotic yeast Saccharomyces cerevisiae CNCM I-3856 on abdominal pain or intestinal discomfort in patients presenting with the irritable bowel syndrome (IBS)

Official Title
-----------------
Effect of S.Cerevisiae vs Placebo on the Improvement of Gastrointestinal Disorders,Especially During Irritable Bowel Syndrome. Randomized, Double-blind Study

Conditions
-----------------
Irritable Bowel Syndrome

Intervention / Treatment
-----------------
* Dietary Supplement: Saccharomyces cerevisiae CNCM I-3856
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: IBS subject meeting the Rome III criteria , with a discomfort or pain present more than 1 day per week in whom organic causes of their symptoms have been excluded IBS-C with less than 3 complete spontaneous bowel movements/week IBS-D with at least 2 or more days/week one stool which has consistency of type 6 or 7 Bristol stool score Subject able of and willing to comply with the protocol and to give their written informed consents Exclusion criteria: History of chronic gastrointestinal disorders History of lactose intolerance History of gluten intolerance Treatment able to influence IBS, modifying intestinal sensitivity and motility (antidepressants,opioid, narcotic analgesics) Eating disorders Pregnancy in progress

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>Dicalcium phosphate, Maltodextrin and Magnesium stearate. | Dietary Supplement: Placebo<br>* Capsule with comparable organoleptic properties and weight than the experimental product. 2 capsules/day during 12 weeks<br>|
| Experimental: Saccharomyces cerevisiae CNCM I-3856<br> | Dietary Supplement: Saccharomyces cerevisiae CNCM I-3856<br>* 2 capsules/day during 12 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in discomfort score,obtained by Daily Likert Scale averaged by week |  | baseline and week 8 |
Markers of Prognosis and Response to Therapy in Patients With Metastatic Brain Tumors Undergoing Stereotactic Radiosurgery (SRS)

Study Overview
=================
Brief Summary
-----------------
This registry study will evaluate patients with metastatic brain tumors undergoing, or having undergone, stereotactic radiosurgery (SRS) at Swedish Medical Center. Clinical outcomes will be evaluated at the 3, 6 and 12-month time points. Clinical data, SRS treatment data, and imaging data (including anatomic and advanced imaging sequences obtained prior to and serially following SRS) will be archived in an online informatics platform, specifically a metastatic brain tumor registry known as the Comprehensive Neuro-oncology Data Repository for Metastatic Tumors (CONDR - Mets).

Conditions
-----------------
Metastatic Brain Tumor

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (>18 yo) with a pathological diagnosis of metastatic brain cancer Participants must have >4 tumors felt to require stereotactic radiosurgery Karnofsky scale of > 70 at the time of initial treatment Age < 80 Exclusion Criteria: Karnofsky scale <70 Age > 80 Inability to undergo MR imaging studies

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantitative measures of overall tumor volume will be performed for each subject at the time of SRS |  | At the time of SRS | 
| Quantitative measures of tumor number will be performed for each subject at the time of SRS |  | At the time of SRS | 
| Overall survival will be measured for each subject (in weeks from SRS to death) |  | Post-SRS | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measures of ADC, rCBV, MTT and ktrans will be performed for each treated tumor at treatment and at 6 months following SRS |  | 6 months post SRS | 
| Time to progression (in weeks) will be measured for each treated tumor |  | Post-SRS | 
| Diagnosis of progression or radiation necrosis (made on clinical reflection at study's end) will be determined for tumors where diagnosis is in question at 6 and 12 months after SRS |  | 12 months post-SRS | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sterotactic Radiosurgery
The Frequency and Risk Factors of Delayed Graft Function

Study Overview
=================
Brief Summary
-----------------
Delayed graft function (DGF) is an important phenomenon after kidney transplantation with direct and indirect implication on graft survival. Although its incidence and risk factors have been studied after cadaveric kidney transplantation cases, only few data is available regarding transplants from living donors. The present study was performed to investigate the frequency and risk factors of DGF among living-unrelated kidney transplant recipients among three transplant centers in part of Middle East.

Detailed Description
-----------------
In this multi-center retrospective study, data from 480 transplanted patients had been collected from existing local hospital registries in three countries (Iran, Kingdom of Saudi Arabia (KSA), and Kuwait) with 3 years post transplantation follow-up. Data for this study was collected based on routine clinical practice of medical practitioners across the participating countries. A case report data collecting form was designed for gathering the data including the recipient and donor's characteristics prior to transplantation, and after transplantation up to three years post transplantation. Using binary logistic regression analysis, the potential risk factors for occurrence of DGF in living donor transplantations were tested. Graft and patient survival at 1, 2 and 3 years depending on follow-up time was evaluated.

Official Title
-----------------
The Frequency and Risk Factors of Delayed Graft Function in Living Donor Kidney Transplantation and Its Clinical Impact in Part of Middle East

Conditions
-----------------
Delayed Graft Function, Kidney Transplant; Complications

Intervention / Treatment
-----------------
* Procedure: living kidney transplantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Living donor kidney recipients with complete prior transplantation data and 3 years post transplantation follow up, including those who died during the observation period Exclusion Criteria: kidney recipients younger than 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| living kidney transplanted patients<br>Any patients over 18 who received kidney transplantation from living donor | Procedure: living kidney transplantation<br>* receiving kidney transplantation from living donor<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of delayed graft function |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| risk factors of DGF |  | three years |